ipi-493 and tanespimycin

ipi-493 has been researched along with tanespimycin* in 4 studies

Trials

1 trial(s) available for ipi-493 and tanespimycin

ArticleYear
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Mar-15, Volume: 13, Issue:6

    To determine the recommended phase 2 dose, dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the heat shock protein (Hsp) 90 inhibitor, 17-allylaminogeldanamycin (17-AAG).. 17-AAG was administered as a 60-min infusion, on days 1, 4, 8, and 11 of a 21-day cycle at dose levels of 150, 200, 270, and 360 mg/m(2)/dose. Pharmacokinetic studies and evaluations for Hsp72 and Akt levels in peripheral blood mononuclear cells were done during the first course of therapy.. Seventeen patients (7 males), median 7 years of age (range, 1-19 years), were enrolled using a standard dose escalation scheme. No DLTs were observed. Although there were no objective responses, three patients remain on therapy at 6+, 7+, and 9+ months with stable disease. One patient with hepatoblastoma had a reduction in alpha-fetoprotein and stable disease over three cycles. At 270 mg/m(2)/dose, the C(max) and areas under the plasma concentration-time curves of 17-AAG were 5,303 +/- 1,591 ng/mL and 13,656 +/- 4,757 ng/mL h, respectively, similar to the exposure in adults. The mean terminal half-life for 17-AAG was 3.24 +/- 0.80 h. Induction of Hsp72, a surrogate marker for inhibition of Hsp90, was detected at the 270 mg/m(2) dose level.. Drug exposures consistent with those required for anticancer activity in preclinical models were achieved without DLT. Evidence for drug-induced modulation of Hsp90 systemically was also detected. The recommended phase II dose of 17-AAG is 360 mg/m(2)/d. Non-DMSO-containing formulations may improve acceptance of this drug by children and their families.

    Topics: Adolescent; Adult; Antineoplastic Agents; Benzoquinones; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; HSP70 Heat-Shock Proteins; Humans; Infant; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Neoplasms; Pediatrics; Recurrence; Treatment Failure

2007

Other Studies

3 other study(ies) available for ipi-493 and tanespimycin

ArticleYear
Heat shock protein 90: inhibitors in clinical trials.
    Journal of medicinal chemistry, 2010, Jan-14, Volume: 53, Issue:1

    Topics: Animals; Benzamides; Benzoquinones; Clinical Trials as Topic; Drug Design; Drug Screening Assays, Antitumor; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Molecular Structure; Purines; Resorcinols; Structure-Activity Relationship

2010
Potent cytotoxic C-11 modified geldanamycin analogues.
    Journal of medicinal chemistry, 2009, May-28, Volume: 52, Issue:10

    17-Allylamino-17-demethoxygeldanamycin (17-AAG) inhibits the activity of Hsp90, an important target for treatment of cancers. In an effort to identify analogues of geldanamycin (GDM) with properties superior to those of 17-AAG, we synthesized C-11 modified derivatives of GDM including ethers, esters, carbazates, ketones, and oximes and measured their affinity for Hsp90 and their ability to inhibit growth of human cancer cells. In accordance with crystal structures reported for complexes of GDMs with Hsp90, bulky groups attached to C-11 interfered with Hsp90 binding while smaller groups such as 11-O-methyl allowed Hsp90 binding. In addition, these analogues also showed in vitro cytotoxicity against human cancer cell lines. Esterification of the 11-OH of 17-AAG eliminated Hsp90 binding in vitro. The readily hydrolyzed esters acted as prodrugs during the measurement of cytotoxicity. Thus, during these experiments, the esters were hydrolyzed, releasing 17-AAG. Several 11-O-methyl-17-alkylaminogeldanamycin analogues were identified with improved potency relative to 17-AAG.

    Topics: Antineoplastic Agents; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Esters; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Prodrugs; Protein Binding; Structure-Activity Relationship

2009
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Journal of medicinal chemistry, 2006, Jul-27, Volume: 49, Issue:15

    17-Allylamino-17-demethoxygeldanamycin (17-AAG)1 is a semisynthetic inhibitor of the 90 kDa heat shock protein (Hsp90) currently in clinical trials for the treatment of cancer. However, 17-AAG faces challenging formulation issues due to its poor solubility. Here we report the synthesis and evaluation of a highly soluble hydroquinone hydrochloride derivative of 17-AAG, 1a (IPI-504), and several of the physiological metabolites. These compounds show comparable binding affinity to human Hsp90 and its endoplasmic reticulum (ER) homologue, the 94 kDa glucose regulated protein (Grp94). Furthermore, the compounds inhibit the growth of the human cancer cell lines SKBR3 and SKOV3, which overexpress Hsp90 client protein Her2, and cause down-regulation of Her2 as well as induction of Hsp70 consistent with Hsp90 inhibition. There is a clear correlation between the measured binding affinity of the compounds and their cellular activities. Upon the basis of its potent activity against Hsp90 and a significant improvement in solubility, 1a is currently under evaluation in Phase I clinical trials for cancer.

    Topics: Animals; Antineoplastic Agents; Benzoquinones; Binding, Competitive; Cell Line, Tumor; Dogs; Drug Screening Assays, Antitumor; Fluorescence Polarization; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Hydroquinones; Lactams, Macrocyclic; Membrane Proteins; Models, Molecular; Protein Isoforms; Receptor, ErbB-2; Rifabutin; Solubility; Structure-Activity Relationship; Water

2006